Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > LATEST
LATEST
-
REGULATORY Pharma, Wholesalers Urge Drug Pricing Overhaul to Address Inflation: LDP Hearing
November 13, 2025
-
REGULATORY Ishin Presses Govt to Commit to OTC-Like Drug Reform by FY2026
November 13, 2025
-
REGULATORY Health Minister Says Govt Mulling Backing for Wholesaler Support
November 13, 2025
-
BUSINESS Meiji, NCC Launch Research on Self-Amplifying mRNA Cancer Vaccine
November 13, 2025
-
BUSINESS Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
November 13, 2025
-
REGULATORY LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
November 12, 2025
-
BUSINESS J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
-
BUSINESS Biogen Launches Higher-Dose Spinraza in Japan
November 12, 2025
-
BUSINESS Meiji Pharma to Set Up Singapore Subsidiary to Drive ASEAN Biz
November 12, 2025
-
BUSINESS Alfresa Deepens Tie-Up with China Wholesaler to Support Japan-to-China Licensing
November 12, 2025
-
BUSINESS Japan’s Generic, Biosimilar Market Seen Topping 2 Trillion Yen in 2033: Fuji Keizai
November 12, 2025
-
REGULATORY Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
November 11, 2025
-
REGULATORY MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
November 11, 2025
-
ORGANIZATION JPMA’s Yoshida Urges Pro-Innovation Rules to Boost Japan’s Appeal amid MFN Fears
November 11, 2025
-
REGULATORY Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
November 11, 2025
-
BUSINESS Japan Ethical Drug Sales Jump 9.7% in September: Crecon
November 11, 2025
-
BUSINESS Kaken’s KP-001 Hits Goal in PIII Vascular Malformation Trial
November 11, 2025
-
COMMENTARY Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
-
BUSINESS MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
-
REGULATORY LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
November 10, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…